FMS (Fresenius Medical Care AG) Moat Score: 6/10 (As of Jun. 25, 2026)


FMS Fresenius Medical Care AG FMS
72 GF Score
Price $23.23
GF Value $24.15
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Fresenius Medical Care AG Moat Score?

Fresenius Medical Care AG FMS -2.60% 72 Moat Score is 6 as of Jun. 25, 2026. GuruFocus rates FMS with a GF Score™ of 72/100 and a GF Value™ of $24.15 (Fairly Valued). The stock has 4 warning signs investors should review. Among 681 Healthcare Providers & Services companies, Fresenius Medical Care AG ranks better than 99.12% on this metric.

Fresenius Medical Care AG has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Fresenius Medical Care AG has Narrow Moat: FMCQF has a strong brand and customer loyalty in the dialysis market, with significant economies of scale. However, while it has some pricing power and regulatory barriers, these are not sufficient to classify it as a wide moat. Its moat is strong but not exceptionally durable.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Fresenius Medical Care AG might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Fresenius Medical Care AG  (NYSE:FMS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Fresenius Medical Care AG Moat Score Related Terms

FMS vs HCA, THC, DVA: Moat Score Comparison

For the Medical Care Facilities subindustry, Fresenius Medical Care AG's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fresenius Medical Care AG Moat Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Fresenius Medical Care AG's Moat Score distribution charts can be found below:

* The bar in red indicates where Fresenius Medical Care AG's Moat Score falls into.


FMS
72GF Score
Fresenius Medical Care AG FMS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Fresenius Medical Care AG (FMS) has a Moat Score of 6 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Fresenius Medical Care AG ranks #6 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 0.90000000000001%.
Is Fresenius Medical Care AG's Moat Score too high?
Fresenius Medical Care AG's current Moat Score is 6. Based on the distribution chart, Fresenius Medical Care AG ranks #6 out of 681 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Fresenius Medical Care AG has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius Medical Care AG's Moat Score compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius Medical Care AG ranks #6 out of 681 companies for Moat Score. This places Fresenius Medical Care AG in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Healthcare Providers & Services company?
A good Moat Score depends on the Healthcare Providers & Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Fresenius Medical Care AG's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius Medical Care AG stock overvalued right now?
Based on GuruFocus' analysis, Fresenius Medical Care AG (FMS) is currently considered Fairly Valued. The stock's GF Value™ is $24.15, compared to a current price of $23.23 — trading 3.8% below its estimated fair value. The current Moat Score is 6. Fresenius Medical Care AG's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Fresenius Medical Care AG (FMS), the current Moat Score is 6 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fresenius Medical Care AG (FMS) Overvalued in 2026?

Based on GuruFocus' analysis, Fresenius Medical Care AG stock appears to be undervalued. The current stock price of $23.23 is trading 3.8% below its estimated GF Value™ of $24.15. GuruFocus considers Fresenius Medical Care AG to be Fairly Valued.

Key valuation signals for FMS:

  • Moat Score: 6
  • GF Value™: $24.15 vs. price of $23.23 (3.8% below fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the FMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fresenius Medical Care AG Business Description

Address Else-Kroner-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
72GF Score

Get the complete analysis for FMS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.23
Price
$24.15
GF Value